# {: m* p: x4 g; k5 ?临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:/ m. {3 X' f2 e, r: @
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.' c; x2 Y. E2 y http://www.ncbi.nlm.nih.gov/pubmed/22968184; J6 m; h' E, b" O3 I) v2 j2 K